Chitomur®
Biologically active food supplement CHITOMUR® contains a complex of low molecular weight pep-
tides with a molecular weight of up to 5000 Da, isolated from the tissues of the bladder wall of young
animals - calves notolder than 12 months of age or pigs.
CHITOMUR® is available in capsules with an active substance content of 10 mg.
Experimental studies have shown that peptides have a tissue-specific effect on the cells of those tis-
sues from which they are isolated. CHITOMUR® peptides regulate metabolic processes in the bladder
wall cells, increase their reserve capacity, have a beneficial effect on the body’s adaptation processes
in extreme conditions, have antioxidant properties, and regulate the processes of peroxidation in the
tissues of the bladder wall. This allows us to assume the effectiveness of the use of CHITOMUR® to
restore the functions of the bladder in case of disorders of various origins.
Among the diseases most common in the elderly, the pathology of the bladder and urinary system
stands out, significantly impairing the quality of life of patients and aggravating the course of concom-
itant pathology. With age, the number of patients with various disorders of the lower urinary tract
function increases significantly, especially in the case of an overactive bladder (OAB). The diagnosis
is made without any hormonal, metabolic, or other apparent diseases (urinary tract infection, bladder
cancer, prostate adenoma, etc.) that can cause the symptoms.
The risk of overactive bladder syndrome increases with age. The critical age is over 60 - among older
people of this age, the prevalence of OAB is at its maximum. The increased risk of OAB for men is ex-
plained, in addition, by benign prostatic hyperplasia, signs of which are present to one degree or an-
other in about half of men aged 60+ years. Nevertheless, the absence of hyperplasia does not exclude
the presence of age-related changes in the bladder, which are almost identical in men and women.
It is believed that the postmenopausal period is also associated with an increased risk of develop-
ing OAB. More than 60% of postmenopausal women suffer from urinary dysfunction. However, the
role of sex hormones is not clear. The results of the use of hormone replacement therapy in these
patients are ambiguous, and instead of improvement, it can lead to a worsening of OAB symptoms.
Thus, a number of anatomical and physiological changes accompanying aging may predispose to the
development of OAB symptoms. Regardless, urinary incontinence should not be considered a natural
sign of aging. In addition, specific functional impairments such as limited mobility, dysfunction of the
upper limbs, and decreased vision can aggravate the course of OAB. It should be kept in mind that
pharmacological drugs used for concomitant diseases can also play a role. For example, diuretics can
significantly increase urinary frequency and mimic OAB symptoms.
Treatment of dysfunction of the bladder depends on the etiology of the pathological condition. In
chronic cystitis, antibiotic therapy is prescribed; with detrusor dysfunction, drugs of the atropine
group are prescribed; in case of neurogenic dysfunction of the bladder, M-anticholinergics (oxybutin,
tolterodine, darifenacin) are prescribed.
CLINICAL CHARACTERISTICS OF PATIENTS
A clinical study of the effectiveness of the use of CHITOMUR® was carried out at the Medical Center
of the St. Petersburg Institute of Bioregulation and Gerontology in the period from March to Novem-
ber 2011. The study involved 28 men aged 45 to 62 with a diagnosis of benign prostatic hyperplasia
(BPH) and 31 women aged 48 to 56 with a diagnosis of overactive bladder (OAB). All patients com-
plained of dysfunction of urination.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.